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Isotonic Designs for Phase I Trials
Denis Heng-Yan Leung, DPhil and You-Gan Wang, DPhil
Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center,
New York, New York (D.H.-Y.L.) and Department of Biostatistics, Harvard School of Public
Health, Boston, Massachusetts (Y.-G.W.)
ABSTRACT: The purpose of a phase I trial in cancer is to determine the level (dose) of the
treatment under study that has an acceptable level of adverse effects. Although substan-
tial progress has recently been made in this area using parametric approaches, the
method that is widely used is based on treating small cohorts of patients at escalating
doses until the frequency of toxicities seen at a dose exceeds a predefined tolerable
toxicity rate. This method is popular because of its simplicity and freedom from paramet-
ric assumptions. In this paper, we consider cases in which it is undesirable to assume a
parametric dose-toxicity relationship. We propose a simple model-free approach by mod-
ifying the method that is in common use. The approach assumes toxicity is nondecreasing
with dose and fits an isotonic regression to accumulated data. At any point in a trial,
the dose given is that with estimated toxicity deemed closest to the maximum tolerable
toxicity. Simulations indicate that this approach performs substantially better than the
commonly used method and it compares favorably with other phase I designs. Control
Clin Trials 2001;22:126–138  Elsevier Science Inc. 2001
KEY WORDS: Continual reassessment method, dose escalation, isotonic regression, maximum tolerated
dose, phase I trials, up-and-down method
INTRODUCTION
One of the primary objectives of a phase I study in cancer is to evaluate
toxicity at different dose levels and recommend a dose that is as high as possible
but safe for patients. This dose is called the maximum tolerated dose (MTD).
A phase I trial usually uses the following design. A fixed number of k doses,
with assumed nondecreasing probabilities of toxicity, are often predetermined.
Cohorts of patients are then treated sequentially, starting at the lowest dose,
until a dose is reached that is deemed to be the best estimate of the MTD.
In this article, we define the MTD as the maximum dose with a probability
of toxicity not exceeding some critical value, say q*. Common phase I trial
designs fall broadly into one of three classes: traditional method, up-and-down
methods, and Bayesian methods. (We omit a fourth group that is based on
stochastic approximation because they are more suitable for bioassays [1].)
The traditional method for cancer phase I trials uses small cohorts of patients
treated at escalating doses. In this method, the decision to escalate or to stop
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the trial at a dose is based on the in-trial frequency of toxicity at that dose.
The method requires no assumptions on the dose-toxicity relationship other
than that the probability of toxicity is nondecreasing with dose.
The up-and-down methods are modifications of the traditional method that
allow escalation as well as de-escalation. Variations of this scheme give different
up-and-down designs. These designs have been studied by a few authors [2, 3].
O’Quigley et al. [4] proposed a Bayesian method that has come to be known
as the continual reassessment method (CRM). The method chooses the MTD
as the dose with toxicity that is deemed closest to the target toxicity, q*. The
original CRM assumed dose level to be on a continuous scale and updated
dose level after every response. The design also allowed multiple dose level
escalations and de-escalations. Subsequent articles on the CRM modified the
design to allow for discrete dose levels [5] and to allow for multiple patients
between updating [6]. Stopping rules based on a predetermined number of
iterations [5–7] and more sophisticated criteria have been studied [8, 9]. Møller
[10] suggested a hybrid up-and-down and CRM method that starts at the lowest
dose and allows only single dose level escalation and de-escalation. O’Quigley
and Shen [11] suggested a non-Bayesian version of the CRM using maximum
likelihood. More recently, Zacks et al. [12] and Babb et al. [13] have studied
Bayesian dose escalation with overdose control (EWOC) that is essentially a
modified CRM. Instead of using a dose with toxicity deemed closest to the
target toxicity at each update, as the CRM does, they used the dose with
probability of higher toxicity than the current estimate of the MTD, not ex-
ceeding some critical value.
As pointed out by Storer [2], large sample properties are not appropriate
for evaluating phase I trial designs, because only a small sample size (around
30) is usually used in phase I trials. Therefore, simulation studies under different
dose-toxicity assumptions are the most convincing ways to evaluate different
methods. A number of simulation reports have been published in the literature
[5, 7, 14]. These studies showed that there can be substantial gains in the chance
of choosing the correct MTD by the CRM over the traditional method that is
in common use. In practice, however, the traditional method still predominates
in phase I designs in the United States. In our opinion, the primary reasons
are: (1) the method is easy to describe and does not require a statistician to
design or evaluate, and (2) no modeling is required beyond an assumption
that the dose-toxicity relationship is nondecreasing.
In this article, we introduce a new method that retains the simplicity of the
traditional design, thereby allowing it to be easily implemented in practice.
The only assumption it uses is that toxicity is nondecreasing with dose. The
method determines escalation and de-escalation after adjusting the toxicity
estimates at each dose to ensure a nondecreasing order. The adjusted toxicity
estimates are obtained from isotonic regression [15] and have simple ana-
lytic expressions.
TRIAL DESIGNS
The Traditional Design
Suppose the k dose levels are d1 , . . . , dk and the corresponding probabilities
of toxicity are Pr(toxicity) 5 0 < q1 , . . . , qk < 1. The traditional method can
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be summarized as follows. Cohorts of M patients are used and the trial begins
at the lowest dose. Dose escalation uses the following scheme, starting at dose
di,i 5 1:
1. Evaluate M patients at di.
(i) If 0 toxic event, escalate to di11.
(ii) If . 0 < m1 toxic events, then go to step 2, otherwise stop and recom-
mend di21 as the MTD.
2. Evaluate an additional M patients at di.
If < m1 1 m2 toxic events are seen in total, then escalate; otherwise stop
and recommend di21 as the MTD.
This strategy uses a maximum of N 5 2k cohorts of M patients each to find
the MTD. When the underlying toxicity is q* 5 0.33, it is common to use values
of M 5 3 and m1 5 1, m2 5 0.
Storer’s Up-and-Down Designs
Storer [2] considered a few simple modifications of the traditional design.
For a tolerable toxicity, q* 5 0.33, he suggested a number of designs: (1) use
cohorts of one patient each and escalate or de-escalate depending on whether
a toxicity is seen; (2) use cohorts of one patient and escalate only after two
consecutive nontoxic responses are seen, but de-escalate whenever a toxic
response is seen; (3) use cohorts of three patients and escalate if no toxic
responses are seen, stay at the same dose if one toxicity is seen, and de-escalate
if more than one toxic response is seen. He also suggested more sophisticated
two-stage designs whereby cohorts of one patient are used for an initial escala-
tion stage until the first toxic response appears, at which point the design
changes to using cohorts of three patients. Fixed total sample sizes of 12(6)36
were considered. At the end of the study, he recommended fitting a parametric
model to the data and finding the MTD via maximum likelihood estimate.
Continual Reassessment Method
The basic ingredient in the CRM is the use of a family of dose-toxicity
functions:
f(d,u), where d1 < d < dk, 0 < f < 1 (1)
that is monotonic in both d and u. It is assumed that for each dose d and
toxicity q, there exists a unique value of u such that f(d, u) 5 q. The target dose
corresponds to a value of d0 such that f(d0, u0) 5 q*. Therefore, to find d0 is
equivalent to finding u0. O’Quigley et al. [4] used a Bayesian approach and
assumed that u follows a prior distribution g(u). The method then approximated
the toxicity at each dose using information from the prior and the dose-toxicity
function. The recommended dose for the next cohort is that with estimated
toxicity closest to q*, among all doses under consideration. This iteration contin-
ues until a fixed number of patients have been tested or a predetermined level
of precision has been reached. The final recommended MTD is the one with
toxicity closest to q* based on the posterior.
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Escalation with Overdose Control
Instead of using the dose with toxicity deemed closest to the target toxicity
for updating, Babb et al. [13] suggested using the highest dose di such that:
Pr(MTD < di|pj) , a (2)
for the j 1 1th cohort, given a tolerance level a and the history up to the jth
cohort. They called 1 – a a Bayesian-feasible level and suggested a value of
0.25 in their study.
Designs Using Isotonic Regression
Here, we introduce a new method by modifying the traditional design. We
only make the assumption that toxicity is nondecreasing with dose.
The method changes the traditional design in two ways. We first discuss
the method of summarizing toxicity risks in our method. When summarizing
toxicity risk at a dose, the traditional design only uses data observed at that
dose but disregards information at other doses. In our opinion, this method
does not make use of the implicitly made assumption of a monotonic dose-
toxicity relationship. A more efficient method would take this into consider-
ation. For example, suppose the trial has just completed testing at dose d3 and
the data history is as follows:
d1 d2 d3
no. tested 6 6 3
no. of toxicities 1 1 0
Then the current practice is to use 1/6, 1/6, and 0/3, respectively, as toxicity
risks at the three doses. However, this clearly violates the monotonicity assump-
tion. Therefore, we suggest that the estimated risks be changed to reflect this.
In this example, we propose the risks at d2 and d3 be first adjusted to 1/9 5 (1
1 0)/(6 1 3). However, this makes the risk at d1 (5 1/6) higher than those at
d2 and d3. Therefore, a further adjustment is used to make all three risks equal
to 2/15 5 (1 1 1)/(9 1 6). In general, if we have tested l levels, the risk at di
(1 < i < l) must satisfy the monotonicity relationship. For any dose dr below
di (r < i) and any dose ds above di (s > i), the pooled estimate of risk can be
expressed as:
wr,i,s 5
osj5r no. of toxicities at dj
osj5r no. tested at dj
(3)
The risk estimate of qi can be estimated using isotonic regression [15]:
qˆi 5
min
i<s<l
max
1<r<i
wr,i,s (4)
The intuition behind Eq. (4) is: if toxicity is monotonic, qˆi must be at least as
large as any of w1,i,s, w2,i,s, . . . , wi,i,s (or the maximum of these) for any s (s > i);
similarly, qˆi must be smaller than any of wr,i,i, wr,i,i11, . . . , wr,i,l (or the minimum
of these) for any r (r < i). It can be easily seen that risks calculated using Eq.
(4) always satisfy the monotonicity assumption.
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We are now ready to summarize the method. Start at dose di, i 5 1:
1. Treat a cohort of M patients at di.
2. Evaluate toxicity at different doses by Eq. (4), and choose the dose at
which qˆi is closest to the tolerable toxicity, q*, where i is the dose last used:
If qˆi , q* by Eq. (4),
5escalate if q* 2 qˆi > qˆi11 2q*,continue at same dose,
i , k
otherwise
(5)
If qˆi > q* by Eq. (4),
5 de-escalate if q* 2 qˆi21 , qˆi2q*,continue at same dose,
i . 1
otherwise
(6)
3. Iterate between steps (1) and (2) and stop when some specified criterion
is met.
This iteration scheme is very simple and involves only an isotonic regression
and a simple comparison at every iteration. The choice of the tolerable toxicity
depends on a number of factors, including target patient population and dis-
ease. In most cancer trials, the value of q* 5 0.33 is commonly used. For q* 5
0.33, M 5 3, the new design treats the initial cohorts quite similarly to the
traditional design. In that situation, the traditional design usually uses m1 5
1, m2 5 0. So if 0/3 toxicities are seen at a dose not previously treated, both
the traditional and the new design will escalate. If 1/3 toxicities are seen, both
will treat another cohort at the same dose. When, however, 2/3 toxicities are
seen, the traditional design stops and chooses the next lowest dose as the MTD,
but the new method will either de-escalate or continue at the same dose (if
already at the lowest dose) and further iteration will occur. We shall see that
this last modification does not lead to a significantly higher proportion being
treated at a very toxic dose. The isotonic regression orders the toxicity in a
monotonic fashion so that dose escalation and de-escalation decisions are obvi-
ous by the comparisons suggested in step (2) in the algorithm.
Stopping Rule
In the new method, one can stop the trial after a fixed number of patients
has been treated. But often, it may be desirable to stop the trial early if there
is sufficient evidence that carrying on further is unlikely to lead to a better
decision. At any point during a trial, if the dose currently indicated as the best
estimate of MTD is dj, we define a better decision than stopping at dj if carrying
on the trial will lead to one of the following actions:
(A1): Escalate to dj11 if dj is lower than the actual MTD, i.e., there is a dose
di . dj, such that qi , q*.
(A2): De-escalate to dj21 if dj has exceeded the actual MTD, i.e., there is a
dose di , dj, such that qi , q* , qj.
The upper bounds to the probabilities of the events A1 and A2 can be calculated
at any time during a trial. If the sum of the upper bounds to Pr(A1) and Pr(A2)
is smaller than some critical value, then we can be certain that carrying on is
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unlikely to lead to a better decision and the trial should be stopped. To calculate
an upper bound for Pr(A1), suppose the current estimates of toxicities at the k
doses are qˆ1, qˆ2, . . . , qˆk and let Y be the random variable denoting the outcome
of the next cohort of M patients treated at dj. If we carry on the trial for another
cohort at dj, the outcome y will be distributed as binomial (M, qj). Therefore,
there is a value 0 < y* < M, such that if y , y*, would lead to escalation to dj11.
In other words, if the current dose is dj, then escalation would occur only if:
q* 2 qˆ9j > qˆ9j11 2 q*, j 1 1 , k (7)
where qˆ9j , qˆ9j11 are new estimates based on the outcome y. The probability of
the above event happening, given that dj is lower than the actual MTD, is
simply Pr(A1) and is bounded above by:
o
y,y*
#q*
0
f(y|M, qj)]qj (8)
where f(y|M, qj) denotes the binomial probability of y. This upper bound
can be calculated by numerical integration. Similarly, an upper bound can be
calculated for Pr(A2).
In practice, we are dealing with a small sample size in a phase I trial.
Therefore, it would be better to recommend a stopping rule that approximates
the above rule and yet is simpler to implement by clinicians. In this article, we
tried a simpler stopping rule of stopping a trial if the same dose has been
indicated consecutively in three (or four) cohorts. In our experience, the simpler
rule and the stopping criterion described above give almost identical conclu-
sions under all practical situations. Therefore, we recommend the simpler rule
as a practical alternative stopping criterion.
Example
Here, we show how the proposed method works in a simulated phase I
trial. We assumed that six dose levels are under consideration and the true
toxicities at the six dose levels were q1 5 0.15, q2 5 0.2, q3 5 0.3, q4 5 0.65, q5 5
0.96, and q6 5 1. The tolerable toxicity q* was set at 0.33, the true MTD was d3.
We allowed cohorts of M 5 3 patients each. The results are shown in Table 1.
The trial started at d1, at which 1/3 patients experienced toxicities. The estimated
toxicity at all doses was 0.33 at that point. So the second cohort was treated
again at d1. A total of 2/6 toxicities were observed following two cohorts with
estimated toxicities at all doses remaining at 0.33. A third cohort was treated
at d1 and following that, 2/9 toxicities were seen and the estimated toxicities
dropped to 0.22 at all doses. At that point, dose escalation occurred for the
fourth cohort. No toxicities were seen for the fourth cohort. Isotonic regression
requires qˆ1 < qˆ2, so these were adjusted to 0.17, 0.17 from their observed values
of 2/9 and 0. A further escalation was indicated for the fifth cohort, because
qˆ2 , q*. The trial carried on to nine cohorts, when three cohorts had been
treated on d3, and d3 was indicated to be the dose for the next cohort. In this
case, it would be highly unlikely that a different dose would be the true MTD
when the trial stopped.
132 D.H.-Y. Leung and Y.-G. Wang
T
ab
le
1
Si
m
ul
at
ed
Ph
as
e
I
T
ri
al
U
si
ng
Pr
op
os
ed
M
et
ho
d
T
re
at
m
en
t
H
is
to
ry
E
st
im
at
ed
T
ox
ic
it
y
C
oh
or
t
d 1
d 2
d 3
d 4
d 5
d 6
qˆ 1
qˆ 2
qˆ 3
qˆ 4
qˆ 5
qˆ 6
C
ur
re
nt
D
os
e
1
no
.t
es
te
d
at
d i
3
0
0
0
0
0
0.
33
0.
33
0.
33
0.
33
0.
33
0.
33
1
no
.o
f
to
xi
ci
ti
es
at
d i
1
0
0
0
0
0
2
no
.t
es
te
d
at
d i
6
0
0
0
0
0
0.
33
0.
33
0.
33
0.
33
0.
33
0.
33
1
no
.o
f
to
xi
ci
ti
es
at
d i
2
0
0
0
0
0
3
no
.t
es
te
d
at
d i
9
0
0
0
0
0
0.
22
0.
22
0.
22
0.
22
0.
22
0.
22
1
no
.o
f
to
xi
ci
ti
es
at
d i
2
0
0
0
0
0
4
no
.t
es
te
d
at
d i
9
3
0
0
0
0
0.
17
0.
17
0.
17
0.
17
0.
17
0.
17
2
no
.o
f
to
xi
ci
ti
es
at
d i
2
0
0
0
0
0
5
no
.t
es
te
d
at
d i
9
3
3
0
0
0
0.
13
0.
13
0.
13
0.
13
0.
13
0.
13
3
no
.o
f
to
xi
ci
ti
es
at
d i
2
0
0
0
0
0
6
no
.t
es
te
d
at
d i
9
3
3
3
0
0
0.
13
0.
13
0.
13
0.
67
0.
67
0.
67
4
no
.o
f
to
xi
ci
ti
es
at
d i
2
0
0
2
0
0
7
no
.t
es
te
d
at
d i
9
3
6
3
0
0
0.
17
0.
17
0.
17
0.
67
0.
67
0.
67
3
no
.o
f
to
xi
ci
ti
es
at
d i
2
0
1
2
0
0
8
no
.t
es
te
d
at
d i
9
3
9
3
0
0
0.
17
0.
17
0.
22
0.
67
0.
67
0.
67
3
no
.o
f
to
xi
ci
ti
es
at
d i
2
0
2
2
0
0
9
no
.t
es
te
d
at
d i
9
3
12
3
0
0
0.
17
0.
17
0.
33
0.
67
0.
67
0.
67
3
no
.o
f
to
xi
ci
ti
es
at
d i
2
0
4
2
0
0
M
5
3,
q*
5
0.
33
.
Phase I Designs 133
NUMERICAL COMPARISON
Now, we evaluate the new design using simulations. We compare it to the
traditional design and Storer’s design using cohorts of three patients (Design
D in [2]). We refer to these as TD and UD-D, respectively. We also include the
CRM and EWOC for comparison. We consider six dose levels (d1 5 21.47, d2 5
21.1, d3 5 20.69, d4 5 20.42, d5 5 0, d6 5 0.42), and we use q* 5 0.33, M 5 3.
Different sets of actual toxicities under the six doses are used. For each set of
toxicities, 1000 Monte-Carlo phase I trials are simulated.
For TD, we use m1 5 1, m2 5 0, which is commonly used in practice. For
the CRM and EWOC, we use the dose-toxicity function:
f(d,u) 5 {(tanhd 1 1)/2}u (9)
with an exponential prior for u. All methods in the simulations use a sequential
dose escalation scheme starting at the lowest dose and with only single dose
escalation and de-escalation allowed. This is in line with ethical requirements
in practice. For the CRM, this requirement corresponds to the modified CRM
studied by Goodman et al. [6]. The original EWOC uses the highest dose di
such that Pr(MTD < di|pj) , a, for the (j 1 1)th cohort, given a tolerance level
a and the history up to the jth cohort. But since multiple dose level escalation
is ethically difficult to justify, in this study we modify it so that if the last
cohort has been treated on dose dl, then escalation occurs if Pr(MTD < dl11|pj) ,
a and de-escalation results if Pr(MTD < dl|pj) . a and continuation at dose
dl otherwise. We use the value of a 5 0.25, as used by Babb et al. [13]. For
UD-D, at the end of a trial, a dose-toxicity model can be fitted to the data and
the MTD estimate found by maximum likelihood. In this study, we use the
same dose-toxicity model as used by EWOC and the CRM. The final dose
recommended by UD-D is the one, among the six doses, that is closest to the
maximum likelihood estimate.
The traditional method stops a trial when two or more toxicities are seen
at any dose level or when two cohorts have been used at the highest dose
level, whichever comes first. For the CRM, EWOC, and UD-D, we use a fixed
sample size of 24 patients. This sample size is chosen based on practicality and
is also close to those used by Storer [2], O’Quigley et al. [4], and Babb et al.
[13]. For the new method, we consider two different stopping criteria. The first
one stops a trial when the same dose has been indicated in three consecutive
cohorts, i.e., two cohorts have been treated at the same dose and continuation
at that dose is indicated for the next cohort; this rule is referred to as IR-A.
The second one uses a fixed sample of 24; this is referred to as IR-B.
The results are given in Tables 2 and 3. Table 2 gives the percentage of
times, out of 1000 trials, that any dose was recommended as the MTD for the
different methods. Table 3 gives the percentage of times a dose below the MTD,
at the MTD, and above the MTD were experimented during the 1000 trials.
We also give the average sample number (ASN) to complete the trial for each
method in Table 2.
Scenarios (a)–(d) represent toxicities that are generated from the dose-toxicity
model used by the CRM and EWOC under different parameter values. Table
2 shows that, except for TD, all methods perform reasonably well. The perfor-
mance of the new method is little affected by the two different stopping rules.
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Table 2 Percent of Maximum Tolerated Dose Recommendations at Different
Doses Using Six Methods
Toxicities Modeled by f(d,u) 5 {(tanhd 1 1)/2}u
Average
Sample
Method Recommendation of d1 to d6 (%) Number
(a) q(i) 0.05 0.10 0.20 0.30 0.50 0.70
EWOC 0.7 18.6 42.6 37.1 1.0 0.0 24.0
CRM 0.0 0.9 14.9 53.4 30.6 0.2 24.0
TD 11.3 27.6 30.6 25.9 4.4 0.2 14.7
UD-D 0.0 0.8 16.2 56.5 26.2 0.3 24.0
IR-A 2.5 10.9 25.0 41.9 17.5 2.2 22.0
IR-B 2.4 11.0 25.1 41.9 18.7 0.9 24.0
(b) q(i) 0.09 0.16 0.27 0.38 0.57 0.75
EWOC 6.3 42.0 36.1 15.5 0.1 0.0 24.0
CRM 0.2 5.5 34.6 49.7 10.0 0.0 24.0
TD 27.2 32.7 25.2 13.8 1.0 0.1 12.8
UD-D 0.4 7.5 35.7 46.7 9.6 0.1 24.0
IR-A 7.2 18.8 32.7 34.7 6.1 0.5 20.8
IR-B 6.7 19.9 31.3 35.0 6.8 0.3 24.0
(c) q(i) 0.30 0.40 0.52 0.61 0.76 0.87
EWOC 89.4 10.2 0.3 0.1 0.0 0.0 24.0
CRM 47.4 38.9 12.8 0.8 0.1 0.0 24.0
TD 84.7 13.2 1.9 0.2 0.0 0.0 7.1
UD-D 56.4 33.4 9.6 0.5 0.1 0.0 24.0
IR-A 55.7 31.9 11.0 1.4 0.0 0.0 15.3
IR-B 54.5 32.9 10.7 1.8 0.1 0.0 24.0
(d) q(i) 0.00 0.00 0.04 0.09 0.25 0.49
EWOC 0.0 0.0 0.0 46.4 53.6 0.0 24.0
CRM 0.0 0.0 0.0 1.7 62.0 36.3 24.0
TD 0.0 1.6 5.4 36.7 45.9 10.4 19.2
UD-D 0.0 0.0 0.0 1.3 57.8 40.9 24.0
IR-A 0.0 0.5 2.3 16.6 45.2 35.4 22.9
IR-B 0.0 0.5 2.3 17.0 51.4 28.8 24.0
Unmodeled Toxicities
Average
Sample
Method Recommendation of d1 to d6 (%) Number
(e) q(i) 0.20 0.90 0.90 0.90 0.90 0.90
EWOC 90.1 9.9 0.0 0.0 0.0 0.0 24.0
CRM 81.6 18.4 0.0 0.0 0.0 0.0 24.0
TD 100.0 0.0 0.0 0.0 0.0 0.0 6.2
UD-D 97.3 2.7 0.0 0.0 0.0 0.0 24.0
IR-A 100.0 0.0 0.0 0.0 0.0 0.0 12.0
IR-B 99.7 0.3 0.0 0.0 0.0 0.0 24.0
(f) q(i) 0.10 0.20 0.90 0.90 0.90 0.90
EWOC 19.5 74.3 6.2 0.0 0.0 0.0 24.0
CRM 6.2 79.6 14.2 0.0 0.0 0.0 24.0
TD 35.7 64.3 0.0 0.0 0.0 0.0 9.4
UD-D 6.3 80.4 13.3 0.0 0.0 0.0 24.0
IR-A 12.8 87.2 0.0 0.0 0.0 0.0 15.0
IR-B 12.6 87.4 0.0 0.0 0.0 0.0 24.0
(continued)
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Table 2 (Continued)
Unmodeled Toxicities
Average
Sample
Method Recommendation of d1 to d6 (%) Number
(g) q(i) 0.30 0.30 0.50 0.50 0.50 0.50
EWOC 80.3 17.2 2.4 0.1 0.0 0.0 24.0
CRM 29.6 42.7 23.1 4.2 0.4 0.0 24.0
TD 75.9 21.1 2.4 0.6 0.0 0.0 7.5
UD-D 38.4 39.8 18.8 2.8 0.2 0.0 24.0
IR-A 40.0 38.2 12.1 5.0 3.0 1.7 16.0
IR-B 33.6 41.8 12.5 6.5 4.1 1.5 24.0
(h) q(i) 0.00 0.00 0.03 0.05 0.11 0.33
EWOC 0.0 0.0 0.0 17.3 82.7 0.0 24.0
CRM 0.0 0.0 0.0 0.0 21.2 78.8 24.0
TD 0.0 1.3 2.3 9.8 50.5 36.1 20.0
UD-D 0.0 0.0 0.0 0.1 19.9 80.0 24.0
IR-A 0.0 0.2 0.5 3.4 29.1 66.8 22.1
IR-B 0.0 0.2 0.5 3.5 32.6 63.2 24.0
(i) q(i) 0.50 0.51 0.52 0.53 0.54 0.55
EWOC 99.6 0.4 0.0 0.0 0.0 0.0 24.0
CRM 90.8 7.0 1.6 0.6 0.0 0.0 24.0
TD 97.4 2.1 0.4 0.1 0.0 0.0 4.9
UD-D 95.0 4.1 0.7 0.2 0.0 0.0 24.0
IR-A 85.5 9.3 3.5 0.8 0.3 0.6 11.6
IR-B 86.8 7.9 3.4 1.0 0.5 0.4 24.0
Based on 1000 simulations for each set of toxicities; q* 5 033. Results at the true MTD are in
bold. EWOC 5 escalation with overdose control; CRM 5 continual reassessment method; TD 5
traditional; UD-D 5 Storer’s design D; IR-A 5 isotonic regression with variable stopping rule;
IR-B 5 isotonic regression with n 5 24.
The fixed sample of 24 (IR-B) gives a slightly higher percentage of correct MTD
recommendations than using a variable stopping rule (IR-A), due to the larger
average number of patients used by the former. Table 3 indicates that EWOC
is most conservative, experimenting the lowest percentage above the MTD.
But this also leads to a more conservative MTD selection. None of the methods
show signs of overaggressiveness. In scenario (b), the CRM and the new method
seem to treat a much higher percentage of the patients above MTD. But a closer
examination reveals that most of these are accounted for by treatment at d5,
which has q5 5 0.38, which is not far from the target level of q* 5 0.33. Note
also that in scenario (c), all designs treat a high percentage of patients above
the MTD. This is due to the fact that in this case, the first dose is already too
toxic. Moreover, most of the patients treated above the MTD are treated at the
next highest dose. In this kind of scenario, the problem really lies in the choice
of the doses used rather than in the designs.
Scenarios (e)–(i) represent situations in which the monotonic dose-toxicity
relationship is unmodeled. All the methods considered here respond well to
sudden and sharp increases in toxicity; none recommend a very toxic MTD
with alarming frequency. When all doses under consideration are at or below
the tolerable toxicity, q*, the CRM, UD-D, and the new method all perform
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Table 3 Proportions of Underdosing, Correct Dosing, and Overdosing Using
Six Methods
Experimentation (%)
Scenario Method Below MTD At MTD Above MTD
(a) EWOC 77.6 20.5 1.9
CRM 49.4 33.8 16.9
TD 72.7 17.6 9.7
UD-D 72.7 24.4 10.3
IR-A 51.4 25.1 23.5
IR-B 56.4 22.7 20.9
(b) EWOC 66.8 23.0 10.1
CRM 32.0 30.5 37.5
TD 57.5 24.5 17.9
UD-D 57.5 30.4 23.0
IR-A 37.0 24.0 39.1
IR-B 41.9 24.5 33.6
(c) EWOC 0.0 82.2 17.8
CRM 0.0 46.7 53.3
TD 0.0 60.4 39.6
UD-D 0.0 56.1 43.9
IR-A 0.0 40.4 59.6
IR-B 0.0 50.5 49.5
(d) EWOC 74.7 25.3 0.0
CRM 51.8 34.7 13.5
TD 66.9 20.7 12.5
UD-D 66.9 27.2 13.7
IR-A 57.6 25.4 17.1
IR-B 57.0 22.6 20.4
(e) EWOC 0.0 88.1 11.9
CRM 0.0 73.2 26.8
TD 0.0 65.0 35.0
UD-D 0.0 67.9 32.1
IR-A 0.0 75.0 25.0
IR-B 0.0 86.8 13.2
(f) EWOC 36.3 54.8 8.9
CRM 17.9 56.2 25.9
TD 39.0 40.0 21.0
UD-D 39.0 53.0 24.1
IR-A 25.8 55.4 18.8
IR-B 22.0 66.2 11.8
(g) EWOC 76.7 19.5 3.8
CRM 38.0 33.9 28.0
TD 55.7 29.3 15.0
UD-D 55.7 35.5 17.0
IR-A 32.2 31.7 36.1
IR-B 40.4 33.0 26.6
(continued)
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Table 3 (Continued)
Experimentation (%)
Scenario Method Below MTD At MTD Above MTD
(h) EWOC 100.0 0.0 0.0
CRM 75.2 24.8 0.0
TD 81.1 18.9 0.0
UD-D 81.1 24.5 0.0
IR-A 77.1 22.9 0.0
IR-B 71.1 29.0 0.0
(i) EWOC 0.0 96.9 3.1
CRM 0.0 79.7 20.3
TD 0.0 84.4 15.6
UD-D 0.0 83.6 16.5
IR-A 0.0 59.9 40.1
IR-B 0.0 77.3 22.7
Based on 1000 simulations for each set of toxicities; q* 5 0.33. EWOC 5 escalation with overdose
control; CRM 5 continual reassment method; TD 5 traditional; UD-D 5 Storer’s design D; IR-A 5
isotonic regression with variable stopping rule; IR-B 5 isotonic regression with n 5 24.
well, but EWOC and TD are both too conservative. When all doses being
considered are above q*, all methods choose the first dose as the MTD with
high frequencies. Once again, the stopping rule has little influence on the
performance of the new method. Table 3 once again highlights that EWOC is
the most conservative method; there are no signs of any method overtreating
a large proportion of patients.
Overall, IR-A and IR-B both perform significantly better than TD. The perfor-
mance of UD-D is slightly better than IR-A and IR-B, but it requires more
patients than IR-A and it requires a parametric likelihood estimate of the MTD
at the end of the trial.
CONCLUSIONS
In phase I trials, one often lacks sufficient knowledge about how toxicity
changes with increasing dose. The traditional method is designed to handle
such situations. However, by using a fixed percentile to stop a trial and also
because it usually tests no more than six patients on a dose, the traditional
design incurs high variability in the estimated MTD. Like the traditional
method, the current method makes the minimal and reasonable assumption
that the dose-toxicity relationship is nondecreasing. It is a simple modification
of a class of designs that is overwhelmingly used in today’s phase I designs.
It is simple to program and very simple to understand. Unlike the traditional
designs, which essentially require q* to be 1/2, 1/3, or 1/4, the method can be
used with any value of q*. In the simulations we performed, we showed that
the method performs much better than the traditional design in all cases, and
competitively with other well-known designs.
The method we propose can be easily changed to optimize efficiency and
resources based on each trial’s requirement. For example, one may consider
starting at a dose other than the lowest dose. Alternatively, a different cohort
size can be used. These parameters depend on the treatment and patient popula-
tion under study and the level of toxicity that is acceptable. If lower dose is
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associated with drug resistance, such as in AIDS trials, one should consider
starting at a high dose. In general, the performance of a particular method
depends on a number of factors, such as the cohort size, the stopping rule, and
the possible constraints in the study. The purpose of this article, however, is
to introduce the conceptual framework of the method and to show that it works
competitively in the scenarios we used here.
In conclusion, we believe that the value of a phase I design is determined
by a balance between efficiency and practicality. A theoretically efficient method
may not be useful if it is logistically difficult to implement or is difficult for
clinicians to understand. The up-and-down method we introduce was designed
with these issues in mind and based on the favorable results we show, we
believe it would be of practical value.
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